Advanced Aesthetic Technologies Announces Appointment of Doug Abel As Chief Executive and President

Feb. 18, 2019 17:04 UTC

BROOKLINE, Mass.--(BUSINESS WIRE)-- Advanced Aesthetic Technologies, Inc. (ATT), a leader in aesthetic gel implant technology, today announced the appointment of Doug Abel as Chief Executive Officer and President, effective immediately. Mr. Abel will lead the Company’s global initiative and advance the development of its gel technology for the aesthetic and healthcare markets.

Richard Burtt, Chairman of Advanced Aesthetic Technologies commented, "We are thrilled to announce the appointment of Doug Abel as Chief Executive and President. Doug brings deep aesthetic technology industry expertise and perspective gained through over 25 years of medical device and specialty pharma experience including senior roles at Sinclair, Allergan, and Biogen. Doug’s successful career of scaling aesthetic businesses and developing and launching new products is ideally suited for AAT’s all-natural gel technology.”

Mr. Abel noted, "I am inspired and excited by the opportunities and tremendous potential of this unique and natural gel technology. The Algeness® gel technology offers a compelling value proposition built on its all-natural composition and true fully biodegradable performance and offers a full product range in aesthetic medicine. I am excited and energized to join the Advanced Aesthetic Technology team and lead the continued development of the Algeness® gel technology."

About Doug Abel

Mr. Abel comes to AAT, Inc after leading the North American operations of Sinclair Pharma since 2015. Doug was responsible for the launch of Sinclair’s aesthetic products in the US and pipeline development efforts to bring an expanded portfolio to the US and Canada. Previously Doug held senior positions at Allergan and Biogen along with several early stage device businesses. During his 25 year experience in aesthetic medicine, Doug has been a member of the Allergan leadership team that built and executed the re-entry into dermatology; both medical dermatology and topical aesthetics/skincare and served as the global lead for BOTOX® aesthetic and hyperhidrosis development and commercial launch initiatives. As VP of Dermatology at Biogen, Doug built and led the team that launched the first Biologic approved for psoriasis. Also, as General Manager of Onset Dermatologics, he built out the commercial team, led the development of multiple new products, and grew revenue over 6 fold.

Doug holds a BA in Chemistry from Lafayette College and an MBA from Temple University.

About the Aesthetic Industry

According to Market Research Future, the global dermal fillers market is expected to grow at a compound annual growth rate of 12.5% over the next five years and is expected to reach $10 billion by 2023. The major factors driving the growth of this market are increased demand by both practitioners and consumers towards the use of minimally invasive and non-invasive procedures.

Worldwide, more than 7-8 million filler procedures are performed annually by plastic surgeons, dermatologists and other practitioners. In the US alone, plastic surgeons performed nearly 3.5 million Hyaluronic Acid filler procedures in 2016, representing over 25% of the non-surgical procedures performed by these surgeons.(1)

About Algeness®

Algeness is the all-natural, biodegradable, biocompatible agarose-based gel implant, free of all synthetic or cross-linking chemicals; and proven through multiple clinical studies in Europe. The uniqueness of Algeness dermal fillers is its abilities to add immediate volume in the facial area with excellent persistence without the added cross-linked chemicals required by all Hyaluronic Acid fillers. Algeness is formulated in several injectable concentrations to match specific cosmetic improvements of the lips, fine lines, and the folds around the mouth and for shaping and volumizing the cheeks, jawline and other areas. With the CE Mark certification, Algeness is available in 33 countries in Europe, South America, Asia, and the Middle East.

(1) 2016 International Study of Cosmetic Surgery, International Society of Aesthetic Plastic Surgery
Algeness® and Master Your Results® are registered trademarks of AAT, Inc. and its subsidiary Algeness-Europe Ltd, Ireland.


Richard Burtt, Chairman
Advanced Aesthetic Technologies, Inc.
Brookline, MA USA


Source: Advanced Aesthetic Technologies, Inc.

Back to news